Physician

Golnaz Javey, MD

According to 2025 Medicare claims, Golnaz Javey, MD (NPI: 1821206897) practices ophthalmology in the Lynchburg, VA market, with the plurality of this provider's patient population coming from Lynchburg City, VA. This provider's primary affiliated billing organization is PIEDMONT EYE CENTER, INC. (NPI: 1801857529; TIN: 54-1120525) and primary practice location at 24502-4271.

Javey's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 2,197 traditional Medicare patients, billed 55,381 HCPCS/CPT codes, and received $2,322,449 in Medicare payments. The top billing code was 67028 (Injection of drug into eye). Part D data shows 1,018 prescription claims across 376 beneficiaries totaling $77,527 in drug costs, led by Restasis (Cyclosporine). Open Payments data shows 150 records totaling $713,339. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,393,060 to $2,322,449. Concurrently, Part D prescription costs have changed little. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$1.2M$2.3M2015 Medicare payment: $1,393,060 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $1,615,406 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $1,386,035 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $1,228,735 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $1,414,915 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $1,310,463 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $1,301,364 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $1,740,623 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $2,228,092 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $2,322,449 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20151,8779,290$1,393,060
20162,0799,616$1,615,406
20172,2229,633$1,386,035
20182,33610,727$1,228,735
20192,30210,080$1,414,915
20201,9708,569$1,310,463
20212,0428,597$1,301,364
20222,1079,082$1,740,623
20232,17337,466$2,228,092
20242,19755,381$2,322,449

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$52K$103K2015 Drug cost: $66,759 (USD; Tot_Drug_Cst)2016 Drug cost: $81,545 (USD; Tot_Drug_Cst)2017 Drug cost: $87,327 (USD; Tot_Drug_Cst)2018 Drug cost: $86,992 (USD; Tot_Drug_Cst)2019 Drug cost: $88,244 (USD; Tot_Drug_Cst)2020 Drug cost: $98,146 (USD; Tot_Drug_Cst)2021 Drug cost: $76,827 (USD; Tot_Drug_Cst)2022 Drug cost: $103,074 (USD; Tot_Drug_Cst)2023 Drug cost: $86,183 (USD; Tot_Drug_Cst)2024 Drug cost: $77,527 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015331828$66,759
2016296830$81,545
2017343862$87,327
2018329813$86,992
2019291789$88,244
2020332978$98,146
2021320778$76,827
2022340817$103,074
2023402900$86,183
20243761,018$77,527

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
67028Injection of drug into eye4181,296$85
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more405417$81
92014Established patient complete exam of visual system908911$75
92012Established patient problem focused exam of visual system659974$60
92134Imaging of retina1,4372,811$28

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
RestasisCyclosporine321,695$34,793
Prednisolone AcetatePrednisolone Acetate2118,572$8,440
ProlensaBromfenac Sodium23878$8,067
Bromfenac SodiumBromfenac Sodium14525$2,322
MoxifloxacinMoxifloxacin Hcl921,841$2,185

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.20$480Apellis Pharmaceuticals, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.130$712,859Roche TCRC, Inc.
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Golnaz Javey, MD?

Tedicare shows public-source Medicare data for Golnaz Javey, MD (NPI 1821206897), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Golnaz Javey, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Golnaz Javey, MD?

Golnaz Javey, MD is linked to PIEDMONT EYE CENTER, INC. (billing NPI 1801857529) in the available physician profile data.

Does Golnaz Javey, MD have Open Payments data?

Golnaz Javey, MD has 150 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.